{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:47:31Z","timestamp":1790416051682,"version":"4.1.0"},"reference-count":104,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Lymphoma is a common and aggressive form of hematopoietic malignancies with diverse clinical and pathological features due to its heterogeneity. Although the current immunochemotherapeutic regimens improve clinical outcomes, many patients still display poor prognosis and frequent relapse. Epigenetic alterations contribute to the progression of lymphoma. DNA methylation and histone methylation are the most common epigenetic alterations and regulate the gene expression involved in lymphoma pathogenesis, including silencing of tumor suppressor genes or activation of proto-oncogenes. Dysregulation or mutation of genes related to DNA methylation, including DNMTs, TET2, IDH2, and genes related to histone methylation, including EZH2, KMT2D has been observed. Most of these alterations are associated with inferior outcomes of patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), peripheral T-cell lymphoma (PTCL), and other subtypes of lymphoma. To overcome the pathogenetic consequence induced by aberrant DNA methylation and histone methylation, novel targeted drugs including azacitidine and decitabine have been gradually applied in practice to enhance the efficacy of current therapy and improve the prognosis of lymphoma patients. Investigating and targeting epigenetic mechanisms in lymphoma could be a key point of future research. Therefore, we mainly summarize the methylation alterations in lymphoma and their respective targeted therapies in this review.<\/jats:p>","DOI":"10.52586\/4970","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T04:48:01Z","timestamp":1632890881000},"source":"Crossref","is-referenced-by-count":28,"title":["Methylation alterations and advance of treatment in lymphoma"],"prefix":"10.31083","volume":"26","author":[{"given":"Meng-Ke","family":"Liu","sequence":"first","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jian","family":"Sun","sequence":"first","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Gao","sequence":"first","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qian","sequence":"first","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"first","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Zhao","sequence":"first","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Dalla-Favera R. Lymphoid malignancies: many tumor types, many altered genes, many therapeutic challenges. Journal of Clinical Investigation. 2012; 122: 3396\u20133397.","DOI":"10.1172\/JCI66307"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375\u20132390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010; 116: 2040\u20132045.","DOI":"10.1182\/blood-2010-03-276246"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. The Lancet. 2017; 390: 298\u2013310.","DOI":"10.1016\/S0140-6736(16)32407-2"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Armitage JO. The aggressive peripheral T-cell lymphomas: 2017. American Journal of Hematology. 2017; 92: 706\u2013715.","DOI":"10.1002\/ajh.24791"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Wang L, Qin W, Huo Y, Li X, Shi Q, Rasko JEJ, et al. Advances in targeted therapy for malignant lymphoma. Signal Transduction and Targeted Therapy. 2020; 5: 15.","DOI":"10.1038\/s41392-020-0113-2"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Taylor KH, Briley A, Wang Z, Cheng J, Shi H, Caldwell CW. Aberrant epigenetic gene regulation in lymphoid malignancies. Seminars in Hematology. 2013; 50: 38\u201347.","DOI":"10.1053\/j.seminhematol.2013.01.003"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Sun XJ, Chen Z, Chen SJ. Mutations in DNA Methyltransferases and Demethylases. In: Boffetta P., Hainaut P. (eds) Encyclopedia of Cancer (pp. 528\u2013537). 3rd edn. Oxford: Academic Press. 2018.","DOI":"10.1016\/B978-0-12-801238-3.65054-7"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein & Cell. 2014; 5: 265\u2013296.","DOI":"10.1007\/s13238-014-0031-6"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Blecua P, Martinez-Verbo L, Esteller M. The DNA methylation landscape of hematological malignancies: an update. Molecular Oncology. 2020; 14: 1616\u20131639.","DOI":"10.1002\/1878-0261.12744"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Ji M, Huang Y, Huang J, Wang Z, Fu D, Liu H, et al. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica. 2018; 103: 679\u2013687.","DOI":"10.3324\/haematol.2017.182444"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Barski A, Cuddapah S, Cui K, Roh T, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007; 129: 823\u2013837.","DOI":"10.1016\/j.cell.2007.05.009"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nature Reviews Clinical Oncology. 2019; 16: 494\u2013507.","DOI":"10.1038\/s41571-019-0190-8"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Duy C, B\u00e9guelin W, Melnick A. Epigenetic Mechanisms in Leukemias and Lymphomas. Cold Spring Harbor Perspectives in Medicine. 2020; 10: a034959.","DOI":"10.1101\/cshperspect.a034959"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Hamidi T, Singh AK, Chen T. Genetic alterations of DNA methylation machinery in human diseases. Epigenomics. 2015; 7: 247\u2013265.","DOI":"10.2217\/epi.14.80"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Wong KK, Lawrie CH, Green TM. Oncogenic Roles and Inhibitors of DNMT1, DNMT3a, and DNMT3B in Acute Myeloid Leukaemia. Biomarker Insights. 2019; 14: 1177271919846454.","DOI":"10.1177\/1177271919846454"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Subramaniam D, Thombre R, Dhar A, Anant S. DNA methyltransferases: a novel target for prevention and therapy. Frontiers in Oncology. 2014; 4: 80.","DOI":"10.3389\/fonc.2014.00080"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Loo SK, Ab Hamid SS, Musa M, Wong KK. DNMT1 is associated with cell cycle and DNA replication gene sets in diffuse large B-cell lymphoma. Pathology, Research and Practice. 2018; 214: 134\u2013143.","DOI":"10.1016\/j.prp.2017.10.005"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Lavoie G, St-Pierre Y. Phosphorylation of human DNMT1: implication of cyclin-dependent kinases. Biochemical and Biophysical Research Communications. 2011; 409: 187\u2013192.","DOI":"10.1016\/j.bbrc.2011.04.115"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Li XY, Li Y, Zhang L, Liu X, Feng L, Wang X. The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt\/betacatenin pathway and DNA methyltransferase-1. Oncology Reports. 2017; 38: 3114\u20133120.","DOI":"10.3892\/or.2017.5945"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Poole CJ, Zheng W, Lodh A, Yevtodiyenko A, Liefwalker D, Li H, et al. DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-all and Burkitt\u2019s lymphoma. Oncotarget. 2017; 8: 76898\u201376920.","DOI":"10.18632\/oncotarget.20176"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Peters SL, Hlady RA, Opavska J, Klinkebiel D, Novakova S, Smith LM, et al. Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas. Molecular and Cellular Biology. 2013; 33: 4321\u20134333.","DOI":"10.1128\/MCB.00776-13"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Yang L, Rau R, Goodell MA. DNMT3a in haematological malignancies. Nature Reviews. Cancer. 2015; 15: 152\u2013165.","DOI":"10.1038\/nrc3895"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. New England Journal of Medicine. 2012; 366: 95\u201396.","DOI":"10.1056\/NEJMc1111708"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. 2012; 119: 559\u2013568.","DOI":"10.1182\/blood-2011-07-369934"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Scourzic L, Couronn\u00e9 L, Pedersen MT, Della Valle V, Diop M, Mylonas E, et al. DNMT3a(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia. 2016; 30: 1388\u20131398.","DOI":"10.1038\/leu.2016.29"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Fukumoto K, Nguyen TB, Chiba S, Sakata-Yanagimoto M. Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. Cancer Science. 2018; 109: 490\u2013496.","DOI":"10.1111\/cas.13393"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Robaina MC, Mazzoccoli L, Arruda VO, Reis FRDS, Apa AG, de Rezende LMM, et al. Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis. Experimental and Molecular Pathology. 2015; 98: 200\u2013207.","DOI":"10.1016\/j.yexmp.2015.03.006"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Amara K, Ziadi S, Hachana M, Soltani N, Korbi S, Trimeche M. DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas. Cancer Science. 2010; 101: 1722\u20131730.","DOI":"10.1111\/j.1349-7006.2010.01569.x"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Alkebsi L, Handa H, Sasaki Y, Osaki Y, Yanagisawa K, Ogawa Y, et al. DNMT3B7 expression related to MENT expression and its promoter methylation in human lymphomas. Leukemia Research. 2013; 37: 1662\u20131667.","DOI":"10.1016\/j.leukres.2013.09.014"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Cogle CR, Scott BL, Boyd T, Garcia-Manero G. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. The Oncologist. 2015; 20: 1404\u20131412.","DOI":"10.1634\/theoncologist.2015-0165"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE. 2010; 5: e9001.","DOI":"10.1371\/journal.pone.0009001"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Liu Y, Wang C, Li X, Dong L, Yang Q, Chen M, et al. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma. Journal for ImmunoTherapy of Cancer. 2021; 9: e002347.","DOI":"10.1136\/jitc-2021-002347"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. Addition of Low-Dose Decitabine to Anti\u2013PD-1 Antibody Camrelizumab in Relapsed\/Refractory Classical Hodgkin Lymphoma. Journal of Clinical Oncology. 2019; 37: 1479\u20131489.","DOI":"10.1200\/JCO.18.02151"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Lio CJ, Yuita H, Rao A. Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies. Blood. 2019; 134: 1487\u20131497.","DOI":"10.1182\/blood.2019791475"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ko M, An J, Pastor WA, Koralov SB, Rajewsky K, Rao A. TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunological Reviews. 2015; 263: 6\u201321.","DOI":"10.1111\/imr.12239"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Yin X, Xu Y. Structure and Function of TET Enzymes. Advances in Experimental Medicine and Biology. 2016; 945: 275\u2013302.","DOI":"10.1007\/978-3-319-43624-1_12"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Nakajima H, Kunimoto H. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis. Cancer Science. 2014; 105: 1093\u20131099.","DOI":"10.1111\/cas.12484"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Rasmussen KD, Helin K. TET1: an epigenetic guardian of lymphomagenesis. Nature Immunology. 2015; 16: 592\u2013594.","DOI":"10.1038\/ni.3176"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nature Immunology. 2015; 16: 653\u2013662.","DOI":"10.1038\/ni.3148"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Beguelin W, Fontan L, et al. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer Discovery. 2018; 8: 1632\u20131653.","DOI":"10.1158\/2159-8290.CD-18-0657"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Chiba S. Dysregulation of TET2 in hematologic malignancies. International Journal of Hematology. 2017; 105: 17\u201322.","DOI":"10.1007\/s12185-016-2122-z"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Kubuki Y, Yamaji T, Hidaka T, Kameda T, Shide K, Sekine M, et al. TET2 mutation in diffuse large B-cell lymphoma. Journal of Clinical and Experimental Hematopathology. 2017; 56: 145\u2013149.","DOI":"10.3960\/jslrt.56.145"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Shingleton JR, Dave SS. TET2 Deficiency Sets the Stage for B-cell Lymphoma. Cancer Discovery. 2018; 8: 1515\u20131517.","DOI":"10.1158\/2159-8290.CD-18-1143"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Mouly E, Ghamlouch H, Della-Valle V, Scourzic L, Quivoron C, Roos-Weil D, et al. B-cell tumor development in Tet2-deficient mice. Blood Advances. 2018; 2: 703\u2013714.","DOI":"10.1182\/bloodadvances.2017014118"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Schwartz FH, Cai Q, Fellmann E, Hartmann S, M\u00e4yr\u00e4np\u00e4\u00e4 MI, Karjalainen-Lindsberg M, et al. TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. Journal of Pathology. 2017; 242: 129\u2013133.","DOI":"10.1002\/path.4898"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Nishizawa S, Sakata-Yanagimoto M, Hattori K, Muto H, Nguyen T, Izutsu K, et al. BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. International Journal of Hematology. 2017; 105: 465\u2013469.","DOI":"10.1007\/s12185-016-2159-z"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Sakata-Yanagimoto M. Multistep tumorigenesis in peripheral T cell lymphoma. International Journal of Hematology. 2015; 102: 523\u2013527.","DOI":"10.1007\/s12185-015-1738-8"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Lemonnier F, Couronn\u00e9 L, Parrens M, Ja\u00efs J, Travert M, Lamant L, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012; 120: 1466\u20131469.","DOI":"10.1182\/blood-2012-02-408542"},{"key":"ref50","unstructured":"Guo YM, Liu XF, Jiao LJ, Yin SY, Wang Z, Li XX, et al. Angioimmunoblastic T-cell lymphoma: histopathological grading and prognosis. Zhonghua Bing Li Xue Za Zhi. 2019; 48: 784\u2013790. (In Chinese)"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2019; 132: 2305\u20132309.","DOI":"10.1182\/blood-2018-04-840538"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Lee S, Urman A, Desai P. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications. Leukemia & Lymphoma. 2019; 60: 2635\u20132645.","DOI":"10.1080\/10428194.2019.1602260"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Zou Y, Zeng Y, Zhang D, Zou S, Cheng Y, Yao Y. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochemical and Biophysical Research Communications. 2010; 402: 378\u2013383.","DOI":"10.1016\/j.bbrc.2010.10.038"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais J, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012; 119: 1901\u20131903.","DOI":"10.1182\/blood-2011-11-391748"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18: 553\u2013567.","DOI":"10.1016\/j.ccr.2010.11.015"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Lemonnier F, Cairns RA, Inoue S, Li WY, Dupuy A, Broutin S, et al. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proceedings of the National Academy of Sciences. 2016; 113: 15084\u201315089.","DOI":"10.1073\/pnas.1617929114"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015; 126: 1741\u20131752.","DOI":"10.1182\/blood-2015-05-644591"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Cai M, Cheng S, Xin W, Hu J, Song Y, Yan Z, et al. CEOP\/IVE\/GDP Alternating Regimen Compared with CEOP as the first-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial. Blood. 2020; 12: 41.","DOI":"10.1186\/s13073-020-00739-0"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Yen K, Travins J, Wang F, David MD, Artin E, Straley K, et al. AG-221, a first-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. Cancer Discovery. 2017; 7: 478\u2013493.","DOI":"10.1158\/2159-8290.CD-16-1034"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Sun X, Chen S, Chen Z. Treating leukemia: differentiation therapy for mIDH2 AML. Cell Research. 2019; 29: 427\u2013428.","DOI":"10.1038\/s41422-019-0173-4"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Lue JK, Amengual JE. Emerging EZH2 Inhibitors and their Application in Lymphoma. Current Hematologic Malignancy Reports. 2018; 13: 369\u2013382.","DOI":"10.1007\/s11899-018-0466-6"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Berg T, Thoene S, Yap D, Wee T, Schoeler N, Rosten P, et al. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood. 2014; 123: 3914\u20133924.","DOI":"10.1182\/blood-2012-12-473439"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Li B, Chng WJ. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. Journal of Hematology & Oncology. 2019; 12: 118.","DOI":"10.1186\/s13045-019-0814-6"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"B\u00e9guelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013; 23: 677\u2013692.","DOI":"10.1016\/j.ccr.2013.04.011"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Heyn H, Esteller M. EZH2: an epigenetic gatekeeper promoting lymphomagenesis. Cancer Cell. 2013; 23: 563\u2013565.","DOI":"10.1016\/j.ccr.2013.04.028"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Tian X, Pelton A, Shahsafaei A, Dorfman DM. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1\/2 and MYC in aggressive B-cell lymphomas. Modern Pathology. 2016; 29: 1050\u20131057.","DOI":"10.1038\/modpathol.2016.114"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Deng Y, Chen X, Huang C, Chen G, Chen F, Lu J, et al. EZH2\/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions. Journal of Cancer. 2019; 10: 2006\u20132017.","DOI":"10.7150\/jca.29807"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Liu Y, Yu K, Li M, Zeng K, Wei J, Li X, et al. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features. Human Pathology. 2017; 64: 213\u2013221.","DOI":"10.1016\/j.humpath.2017.04.011"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics. 2010; 42: 181\u2013185.","DOI":"10.1038\/ng.518"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Zhao Z, Chen L, Dawlaty MM, Pan F, Weeks O, Zhou Y, et al. Combined Loss of Tet1 and Tet2 Promotes B Cell, but not Myeloid Malignancies, in Mice. Cell Reports. 2015; 13: 1692\u20131704.","DOI":"10.1016\/j.celrep.2015.10.037"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu J, Paulk J, et al. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nature Medicine. 2016; 22: 632\u2013640.","DOI":"10.1038\/nm.4092"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, et al. Mutation of a677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proceedings of the National Academy of Sciences of the United States of America. 2012; 109: 2989\u20132994.","DOI":"10.1073\/pnas.1116418109"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Huet S, Xerri L, Tesson B, Mareschal S, Taix S, Mescam-Mancini L, et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer Journal. 2017; 7: e555.","DOI":"10.1038\/bcj.2017.32"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Giulino-Roth L. EZH2: a potential new target in T-cell lymphoma? Leukemia & Lymphoma. 2015; 56: 1924\u20131925.","DOI":"10.3109\/10428194.2014.987770"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Zhang H, Lv H, Jia X, Hu G, Kong L, Zhang T, et al. Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma. Oncology Letters. 2019; 18: 1415\u20131423.","DOI":"10.3892\/ol.2019.10410"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Liu J, Liang L, Huang S, Nong L, Li D, Zhang B, et al. Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK\/T-cell lymphoma, nasal type, is associated with disease progression and prognosis. Human Pathology. 2019; 83: 166\u2013176.","DOI":"10.1016\/j.humpath.2018.08.025"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Gulati N, B\u00e9guelin W, Giulino-Roth L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leukemia & Lymphoma. 2018; 59: 1574\u20131585.","DOI":"10.1080\/10428194.2018.1430795"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang K, Xiao Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Molecular Cancer Therapeutics. 2014; 13: 842\u2013854.","DOI":"10.1158\/1535-7163.MCT-13-0773"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Italiano A, Soria J, Toulmonde M, Michot J, Lucchesi C, Varga A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncology. 2018; 19: 649\u2013659.","DOI":"10.1016\/S1470-2045(18)30145-1"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncology. 2020; 21: 1433\u20131442.","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492: 108\u2013112.","DOI":"10.1038\/nature11606"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Smonskey M, Lasorsa E, Rosario S, Kirk JS, Hernandez-Ilizaliturri FJ, Ellis L. EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis. Oncoscience. 2016; 3: 21\u201330.","DOI":"10.18632\/oncoscience.288"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot J, et al. Phase i Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clinical Cancer Research. 2019; 25: 7331\u20137339.","DOI":"10.1158\/1078-0432.CCR-18-4121"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Rao RC, Dou Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nature Reviews. Cancer. 2015; 15: 334\u2013346.","DOI":"10.1038\/nrc3929"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Kwon M, Park K, Hyun K, Lee J, Zhou L, Cho Y, et al. H2B ubiquitylation enhances H3K4 methylation activities of human KMT2 family complexes. Nucleic Acids Research. 2020; 48: 5442\u20135456.","DOI":"10.1093\/nar\/gkaa317"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011; 476: 298\u2013303.","DOI":"10.1038\/nature10351"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood. 2018; 131: 595\u2013604.","DOI":"10.1182\/blood-2017-08-737361"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Huang Y, Cai K, Xu P, Wang L, Huang C, Fang Y, et al. CREBBP\/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis. Signal Transduction and Targeted Therapy. 2021; 6: 10.","DOI":"10.1038\/s41392-020-00437-8"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nature Medicine. 2015; 21: 1199\u20131208.","DOI":"10.1038\/nm.3943"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Ferrero S, Rossi D, Rinaldi A, Bruscaggin A, Spina V, Eskelund CW, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020; 105: 1604\u20131612.","DOI":"10.3324\/haematol.2018.214056"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Lee S, Park HY, Kang SY, Kim SJ, Hwang J, Lee S, et al. Genetic alterations of JAK\/STAT cascade and histone modification in extranodal NK\/T-cell lymphoma nasal type. Oncotarget. 2015; 6: 17764\u201317776.","DOI":"10.18632\/oncotarget.3776"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Li Q, Zhang W, Li J, Xiong J, Liu J, Chen T, et al. Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK\/T-cell lymphoma. Biomarker Research. 2020; 8: 27.","DOI":"10.1186\/s40364-020-00205-4"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Lan Q, Liu PY, Haase J, Bell JL, H\u00fcttelmaier S, Liu T. The Critical Role of RNA m6a Methylation in Cancer. Cancer Research. 2019; 79: 1285\u20131292.","DOI":"10.1158\/0008-5472.CAN-18-2965"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Yao L, Yin H, Hong M, Wang Y, Yu T, Teng Y, et al. RNA methylation in hematological malignancies and its interactions with other epigenetic modifications. Leukemia. 2021; 35: 1243\u20131257.","DOI":"10.1038\/s41375-021-01225-1"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Cheng Y, Fu Y, Wang Y, Wang J. The m6A Methyltransferase METTL3 Is Functionally Implicated in DLBCL Development by Regulating m6A Modification in PEDF. Frontiers in Genetics. 2020; 11: 955.","DOI":"10.3389\/fgene.2020.00955"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Kuai Y, Gong X, Ding L, Li F, Lei L, Gong Y, et al. Wilms\u2019 tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90. Cell Communication and Signaling. 2018; 16: 50.","DOI":"10.1186\/s12964-018-0258-6"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Han H, Fan G, Song S, Jiang Y, Qian C, Zhang W, et al. PiRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6a RNA methylation in DLBCL. Blood. 2021; 137: 1603\u20131614.","DOI":"10.1182\/blood.2019003764"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Ma H, Shen L, Yang H, Gong H, Du X, Li J. m6A methyltransferase Wilms\u2019 tumor 1-associated protein facilitates cell proliferation and cisplatin resistance in NK\/T cell lymphoma by regulating dual-specificity phosphatases 6 expression via m6A RNA methylation. IUBMB Life. 2021; 73: 108\u2013117.","DOI":"10.1002\/iub.2410"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Wu G, Suo C, Yang Y, Shen S, Sun L, Li ST, et al. MYC promotes cancer progression by modulating m(6) A modifications to suppress target gene translation. EMBO Reports. 2021; 22: e51519.","DOI":"10.15252\/embr.202051519"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Watatani Y, Sato Y, Miyoshi H, Sakamoto K, Nishida K, Gion Y, et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019; 33: 2867\u20132883.","DOI":"10.1038\/s41375-019-0473-1"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Hartmann EM, Be\u00e0 S, Navarro A, Trapp V, Campo E, Ott G, et al. Increased tumor cell proliferation in mantle cell lymphoma is associated with elevated insulin-like growth factor 2 mRNA-binding protein 3 expression. Modern Pathology. 2012; 25: 1227\u20131235.","DOI":"10.1038\/modpathol.2012.84"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Esteve-Puig R, Climent F, Pi\u00f1eyro D, Domingo-Dom\u00e8nech E, Davalos V, Encuentra M, et al. Epigenetic loss of m1a RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome. Blood. 2021; 137: 994\u2013999.","DOI":"10.1182\/blood.2020005823"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Schaefer M, Hagemann S, Hanna K, Lyko F. Azacytidine Inhibits RNA Methylation at DNMT2 Target Sites in Human Cancer Cell Lines. Cancer Research. 2009; 69: 8127\u20138132.","DOI":"10.1158\/0008-5472.CAN-09-0458"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Cheng JX, Chen L, Li Y, Cloe A, Yue M, Wei J, et al. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nature Communications. 2018; 9: 1163.","DOI":"10.1038\/s41467-018-04518-9"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/26\/9\/10.52586\/4970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T06:23:27Z","timestamp":1732688607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/26\/9\/10.52586\/4970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"alternative-id":["s2768-6701(21)00031-9"],"URL":"https:\/\/doi.org\/10.52586\/4970","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"article-number":"602"}}